Incidence of Acute Myocardial Infarction Following Large-Volume Pleurocentesis
The incidence of acute myocardial infarction (AMI) following large-volume pleurocentesis is extremely rare and not specifically documented in major pleural disease guidelines or large-scale studies. While cardiovascular complications can occur after pleural procedures, AMI is not among the commonly reported or tracked complications.
What the Evidence Actually Shows
Documented Complications of Large-Volume Pleurocentesis
The major guidelines on pleural effusion management 1, 2 consistently identify the following as the primary complications of thoracentesis:
- Pneumothorax: Most common complication, occurring in approximately 6% of cases overall 2, with rates as low as 1-4% when ultrasound guidance is used 1
- Re-expansion pulmonary edema: A recognized but uncommon complication following drainage of large effusions 3
- Bleeding/hemothorax: Very rare, approximately 3 per 1,000 procedures 2
- Solid organ puncture: Rare, reduced with ultrasound guidance 1
Notably absent from these comprehensive guidelines is any mention of AMI as a recognized complication of pleurocentesis.
Cardiovascular Events in Pleural Disease Context
The most relevant evidence comes from a 2026 study examining cardiovascular complications after pleural infection (not simple pleurocentesis) 4. This study found:
- 24% of patients with pleural infection developed cardiovascular events within 1 year
- AMI occurred in only 2% of these patients (9 out of 434 patients with pleural infection)
- Most events (85%) occurred within 28 days of presentation
- The primary cardiovascular events were heart failure (11%) and arrhythmia (9%), not AMI
Critical distinction: These cardiovascular events were associated with the underlying pleural infection and systemic inflammatory response, not the drainage procedure itself.
Post-Cardiac Surgery Context
In patients undergoing pleurocentesis after cardiac surgery 5, the focus is on:
- Drainage volumes and transfusion requirements
- Recurrence rates (approximately 21%)
- Need for repeat procedures
- No mention of AMI as a complication of the drainage procedure
Clinical Implications
Why AMI is Not a Recognized Complication
Hemodynamic changes are generally well-tolerated: Large-volume thoracentesis causes gradual hemodynamic shifts that do not typically precipitate acute coronary events in patients without critical coronary disease
The procedure itself is low-risk: Unlike procedures involving direct cardiac manipulation or significant hemodynamic stress, pleurocentesis is a relatively benign intervention from a cardiovascular standpoint
Other complications dominate the risk profile: Pneumothorax and re-expansion pulmonary edema are the complications that warrant monitoring, not AMI
When to Consider Cardiovascular Risk
Based on the available evidence, consider heightened cardiovascular monitoring in patients with:
- Pre-existing heart failure (OR 7.99 for cardiovascular events) 4
- History of arrhythmia (OR 2.89) 4
- Active smoking history (OR 1.99) 4
- Elevated serum urea (marker of renal dysfunction and cardiovascular risk) 4
- Advanced age 4
However, even in these high-risk patients, the concern is primarily for heart failure decompensation or arrhythmia, not AMI.
Practical Recommendations
For routine large-volume pleurocentesis:
- AMI risk does not require specific monitoring beyond standard vital signs
- Focus monitoring on respiratory status (for re-expansion pulmonary edema) and pneumothorax detection
- Post-procedure chest X-ray is recommended to detect pneumothorax 6, not for cardiac complications
For patients with known coronary artery disease:
- While theoretical risk exists, no evidence supports routine cardiac biomarker monitoring or ECG after uncomplicated pleurocentesis
- Standard procedural precautions and hemodynamic monitoring are sufficient
Common Pitfall to Avoid
Do not conflate cardiovascular events occurring in the context of pleural infection or systemic illness with complications directly attributable to the pleurocentesis procedure itself. The 2% AMI rate in pleural infection patients 4 reflects the severity of the underlying infectious/inflammatory process, not the drainage procedure.
Bottom line: If you are asking about AMI risk to inform consent or monitoring protocols for large-volume pleurocentesis, the answer is that this is not a recognized or documented complication requiring specific surveillance or patient counseling beyond standard procedural risks.